{"filing":{"accession_number":"0001213900-26-079824","cik":"0001937993","ticker":"CVKD","company_name":"Cadrenal Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"ea0298669-8k_cadrenal.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026079824/ea0298669-8k_cadrenal.htm"},"events":[{"id":18990,"run_id":17090,"accession_number":"0001213900-26-079824","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cadrenal announced a comprehensive strategic realignment of its clinical portfolio into a \"Cardiac Acute Critical Care Franchise\" and initiated a structured process to secure out-licensing, portfolio monetization, or commercial co-development partnerships for late-stage assets. This represents a material shift in the company's business model and operational strategy—from internal development to a partnership-driven model—which would affect a reasonable investor's assessment of the company's path to commercialization and capital efficiency. While the filing does not disclose a completed M\u0026A transaction or specific partnership agreement, the strategic portfolio reorganization and active partnering process constitute a material operational and strategic business event.","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":17960,"accession_number":"0001213900-26-079824","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Cadrenal announced a comprehensive strategic realignment of its clinical portfolio into a \"Cardiac Acute Critical Care Franchise\" and initiated a structured process to secure out-licensing, portfolio monetization, or commercial co-development partnerships for late-stage assets. This represents a material shift in the company's business model and operational strategy—from internal development to a partnership-driven model—which would affect a reasonable investor's assessment of the company's path to commercialization and capital efficiency. While the filing does not disclose a completed M\u0026A transaction or specific partnership agreement, the strategic portfolio reorganization and active partnering process constitute a material operational and strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T12:31:56.555834+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-07-21"}]}